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Abstract
Deregulation of the mammalian target of rapamycin (mTOR) signaling pathway has been found in a variety of
human cancers. However, the exact molecular mechanism how the mTOR signaling pathway is regulated remains
largely elusive. Recently, DEPTOR was identified as an endogenous mTOR inhibitor that could suppress mTOR
activity in vivo. More importantly, accumulated evidence has implicated that DEPTOR plays a pivotal role in the
development and progression of human malignances, which could in part be mediated through its inhibitory role
toward mTOR. Furthermore, three independent laboratories including our own have demonstrated that the stability
of DEPTOR is controlled by the SCFβ-TrCP E3 ubiquitin ligase and deregulated DEPTOR destruction might con-
tribute to hyperactivation of mTOR in pathologic conditions including cancer. This review discusses the recent
literature regarding the function of DEPTOR involved in cell growth, apoptosis, autophagy, epithelial-mesenchymal
transition, and drug resistance, all of which are associated with the pathogenesis of human cancers. Moreover,
we also summarize that targeting DEPTOR may be a novel strategy for achieving better anticancer treatments.
Neoplasia (2012) 14, 368–375
Introduction
Although many scientists and physicians have made significant efforts to
fight cancers for the past several decades, cancer is still one of the most
common causes of deaths in the world [1]. For example, statistical evi-
dence shows that there is one in four deaths due to cancer in the United
States. Moreover, it has an estimated 1,638,910 new cancer cases and
577,190 cancer-causing deaths that are projected to occur in 2012 [1].
Unfortunately, the 5-year relative survival rate for all human cancers diag-
nosed is 66% at present [1], suggesting that cancer is still a major health
problem in the United States, just falling short of cardiovascular/heart
disease. The causes responsible for cancer development and progression
have been intensively investigated during the past 50 years; however, the
molecular mechanisms of carcinogenesis are still poorly understood.
Toward the major strides to better understand cancer-causing
mechanisms, in the recent years, many studies have demonstrated
that multiple signaling pathways are involved in tumorigenesis such
as phosphatidylinositol-3 kinase (PI3K)/Akt, Hedgehog, mammalian
target of rapamycin (mTOR), nuclear factor κB, epidermal growth
factor receptor, platelet-derived growth factor, extracellular signal–
regulated kinase, fibroblast growth factor, mitogen-activated protein
kinase, insulin-like growth factor, Notch, Ras, and the WNT/β-
catenin signaling pathway [2–13]. Among these signaling pathways,
the mTOR pathway received increased attention because mounting
evidence has demonstrated that targeting the mTOR pathway could
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be a promising anticancer therapeutic option [14]. More importantly,
many mTOR inhibitors that have been and are undergoing clinical
trials to fight against various types of human cancers have been de-
veloped [15]. However, the outputs of these agents that have already
underwent clinical trials are not favorable due in part to the compli-
cated regulatory mechanisms composed of multiple feedback loops for
the mTOR signaling pathway. Therefore, a better understanding of
how mTOR activity is regulated by the interwoven network of signal-
ing circuits in normal physiology as well as in various pathologic con-
ditions will provide insights into better clinical intervention with the
mTOR inhibitors. To that end, the group led by Dr David Sabatini
recently found an endogenous mTOR inhibitor, DEPTOR, which is
overexpressed in multiple myeloma cells and required for their survival
[16]. More recently, we and other two groups independently reported
that the stability of DEPTOR is governed by SCFβ-TrCP (β-transducin
repeat-containing protein), an E3 ubiquitin ligase [17–19]. Accumu-
lated evidence has also demonstrated that DEPTOR plays pivotal
roles in tumorigenesis. Therefore, in the following sections, we will
summarize what is currently known regarding DEPTOR in the tumori-
genesis and how these newly generated knowledge in DEPTOR regu-
lation would be helpful for designing novel therapeutic strategies
through targeting DEPTOR toward achieving a better treatment
outcome for a subset of human cancer patients.
mTOR Signaling Pathway
mTOR belongs to the PI3K-related protein kinase subfamily that plays
a pivotal role in the regulation of various cellular processes including cell
growth, apoptosis, and cell metabolism [20]. As illustrated in Figure 1,
mTOR consists of two distinct subcomplexes, termed mTOR com-
plex 1 (mTORC1) and 2 (mTORC2), which have slight differences
in the subunit compositions, and thus physiological functions [20].
Specifically, mTORC1 consists of five components, mTOR, Raptor
(regulatory-associated protein of mTOR), mLST8/GβL (mammalian
lethal with Sec13 protein 8/G protein β-subunit-like protein), PRAS40
(proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP-domain-
containing mTOR-interacting protein) [20]. mTORC2 is composed
of six components, including mTOR, Rictor (rapamycin-insensitive
companion of mTOR), mLST8/GβL, DEPTOR, PROTOR (protein
observed with Rictor 1)/PRR5 (proline-rich protein 5), and mitogen-
activated protein kinase–associated protein 1 (also known as mSIN1)
[20]. Both biochemical and genetic studies have established that mTOR
is an important sensor of various metabolic and nutrient stresses, receiv-
ing and interpreting environmental inputs and transducing them to the
downstream signaling pathways to control cellular metabolism, cellular
growth, and survival [21].
It is known that mTORC1 activates protein synthesis, nutrient trans-
port, lipid synthesis, cell growth, and other processes in response to
several stresses including growth factors, low energy, and nutrients.
In addition, functioning as a nutrient and energy sensor, mTORC1
negatively regulates autophagy, a process that is necessary for cell sur-
vival under the starvation condition [14]. More specifically, under
unfavorable nutrient conditions (low-energy state) including serum
or glucose starvation, mTORC1 kinase activity is kept low, and cel-
lular metabolism and growth are therefore restrained at basal levels.
When cells are shifted to a more favorable environment (high-energy
state), mTORC1 signaling is activated to stimulate cell metabolism
Figure 1. Schematic illustration of themTOR signaling pathway. AMPK indicates AMP-activated kinase; ATG13, autophagy-related protein 13;
DEPTOR, DEP-domain-containing mTOR-interacting protein; 4E-BP1, eukaryotic initiation factor 4E-binding protein 1; HIF-1α, hypoxia-
inducible factor 1α; mLST8/GβL, mammalian lethal with Sec13 protein 8/G protein β-subunit-like protein; mSin1, stress-activated protein
kinase interacting protein; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; PDCD4,
programmed cell death 4; PI3K, phosphatidylinositol 3-kinase; PRAS40, proline-rich Akt substrate of 40 kDa; PRR5, proline-rich protein 5;
PROTOR, protein observed with Rictor-1; Raptor, regulatory-associated protein of mTOR; REDD1, regulated in development and DNA
damage response 1; Rheb, Ras homolog enriched in brain; Rictor, rapamycin-insensitive companion ofmTOR; S6K, ribosomal p70 S6 kinase;
TSC, tuberous sclerosis complex.
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and cell growth [14,22]. mTORC1 exerts its regulatory functions
partly through phosphorylating downstream targets such as two
well-characterized target proteins S6K (p70 S6 ribosomal kinase)
and 4E-BP1 (the eukaryotic translation initiation factor 4E-binding
protein 1) [14]. Nevertheless, mTORC2 functions as an Akt- and
SGK1-activating kinase, which phosphorylates the hydrophobic motif
of Akt at Ser473 and SGK1 (serum/glucocorticoid regulated kinase 1)
at Ser422, leading to full activation of the Akt and SGK1 kinase [14].
In addition, mTORC2 mediates the actin cytoskeletal organization,
thereby playing a critical role in tumor cell motility, invasiveness and
metastasis [23]. However, given the critical role of mTOR kinases in
cell fate control, it remains largely unknown how the activation of
mTOR kinase activity is regulated in vivo.
DEPTOR as an mTOR Inhibitor
It is noteworthy that the exact functions as well as the regulatory
mechanisms of each component in mTORC1 and mTORC2 cur-
rently are not fully understood. Recently, Peterson et al. [16] made
a groundbreaking contribution by demonstrating a critical function
of DEPTOR in mTOR pathway. They found that DEPTOR is part
of mTORC1 and mTORC2 and interacts specifically with mTOR
[16]. Moreover, DEPTOR depletion activates both mTORC1 and
mTORC2 signaling and enhances the in vitro kinase activities of both
complexes, suggesting that DEPTOR is an inhibitor of mTORC1 and
mTORC2 kinase activities [16]. Furthermore, both mTORC1 and
mTORC2 could negatively regulate the expression of DEPTOR at
both transcriptional and posttranslational levels [16]. More impor-
tantly, mTOR-dependent phosphorylation of DEPTOR promotes its
release from mTOR, thereby releasing its inhibitory role. Consistent
with this notion, overexpression of DEPTOR inhibits mTORC1 sig-
naling. However, elevated expression of DEPTOR unexpectedly acti-
vates the Akt signaling, in part due to DEPTOR-mediated suppression
of the S6K-dependent negative feedback loop toward the IRS1-PI3K-
Akt signaling axis [16]. Taken together, these findings suggest that
DEPTOR functions as an endogenous inhibitor of mTOR.
Regulation of DEPTOR by the E3 Ubiquitin
Ligase SCFβ-TrCP
The 26S proteasomal destruction pathway has been previously impli-
cated in the regulation of the mTOR signaling pathway [24]. It has
been found that cells displayed a significant decrease in mTORC1 ac-
tivity when treated with the proteasomal inhibitor, MG132 [24]. Al-
though Raptor was demonstrated to associate with Cullin-4 [24], it
remains largely unknown how the ubiquitin destruction pathway par-
ticipates in the regulation of the mTOR signaling pathway. Recently,
our studies provided strong experimental evidence that SCFβ-TrCP–
dependent destruction of the mTOR inhibitor, DEPTOR, governs
mTOR activity and, subsequently, cellular response to environmental
stresses. At the same time, two other independent groups also identified
that the stability of DEPTOR is regulated by the β-TrCP–containing
E3 ubiquitin ligase [17–19]. Here, we will briefly discuss how β-TrCP
can influence mTOR signaling by promoting the ubiquitination and
subsequent destruction of its endogenous inhibitor, DEPTOR.
SCFβ-TrCP as the Putative E3 Ligase Responsible for
DEPTOR Destruction
β-TrCP is one of the F-box family of proteins, which forms a multi-
component SCF (Skp1-Cullin-1-F-box) type of E3 ubiquitin ligase
complex. Recent studies have identified multiple specific substrates
of β-TrCP including Cdc25a [25,26], β-catenin [27,28], caspase 3
[29], Emi1 [30,31], Mdm2 [32], IκB [33], PDCD4 (programmed
cell death 4) [34], Snail [35], Claspin [36], REST (RE1-silencing
transcription factor) [37,38], BimEL (Bcl-2 interacting mediator of
cell death extra long) [39], and Wee1 [40]. However, until now,
there is no characterized role for β-TrCP in either cellular metabo-
lism or mTOR signaling regulation. To that end, we recently found
that DEPTOR interacts with β-TrCP and that SCFβ-TrCP controls
DEPTOR abundance, suggesting that SCFβ-TrCP could be a candidate
E3 ubiquitin ligase for DEPTOR [18]. Importantly, the research group
led by Dr Michele Pagano also found that serum stimulation led
to a significant increase in the binding of DEPTOR to endogenous
β-TrCP, indicating that DEPTOR is a serum-dependent ubiquitin
substrate of β-TrCP [17]. Moreover, silencing endogenous β-TrCP
increased the DEPTOR half-life on serum stimulation, indicating that
β-TrCP indeed controls the DEPTOR stability, a critical negative
regulator of mTOR activation [17]. Consistent with this notion, the
results reported independently fromDr Yi Sun’s laboratory also showed
that DEPTOR binds to β-TrCP and SCF complex through which its
stability is negatively regulated by β-TrCP [19]. Furthermore, β-TrCP
shortens the DEPTOR protein half-life and promotes DEPTOR
ubiquitination [19]. Taken together, three groups independently iden-
tified SCFβ-TrCP as an E3 ligase that governs DEPTOR degradation.
DEPTOR Degron Is Controlled by Phosphorylation
It is known that there are two required conditions for β-TrCP
to promote the degradation of its substrates: 1) most substrates typi-
cally containing the canonical DSGxxS phospho-degron and 2) proper
phosphorylation of the substrate by one or a combination of various
kinases is required for recognition by β-TrCP [41]. Unexpectedly,
DEPTOR does not contain a canonical DpSGxxpS degron that
could be recognized by SCFβ-TrCP; instead, it contains a derivative
pS/TpSGxxpS phospho-degron variant [18]. More importantly, Duan
et al. [17] found that phosphorylation of all three serine residues
within the putative DEPTOR phospho-degron (Ser286, Ser287,
and Ser291) is required for the interaction between DEPTOR and
β-TrCP. Consistently, Zhao et al. [19] reported that phosphorylation
of Ser293 and Ser299 may function to prime the phosphorylation
of Ser286, Ser287, and Ser291. Similarly, using a combination of
biochemical assays coupled with mass spectrometry analysis, we also
identified that phosphorylation of multiple sites (S286, S287 S265,
S286, S293, T295, and S299) within DEPTOR is necessary for its
interaction with β-TrCP [18].
Casein Kinase I Participates in the Regulation of
DEPTOR Stability
Because phosphorylation of the substrates within their phospho-
degrons is a prerequisite for proper destruction mediated by the
SCFβ-TrCP E3 ubiquitin ligase complex, we were therefore interested
in further defining the upstream kinases responsible for phosphory-
lating DEPTOR, which triggers its interaction with β-TrCP. Our
dedicated efforts with various biochemical analyses revealed a possible
role for casein kinase I (CKI) in the regulation of DEPTOR stability.
CKI, one of the first identified kinases, phosphorylates many down-
stream targets to participate in a wide range of cellular processes in-
cluding cell cycle progression, circadian cycle, and apoptosis [42,43].
Interestingly, many well-characterized β-TrCP substrates including
β-catenin [44], Period 1 [45] andMdm2 [32] are CKI substrates as well,
and phosphorylation by CKI is required for their efficient recognition
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and ubiquitination by β-TrCP. Unlike other kinases such as Akt and
mTOR [46], the activity of CKI is considered relatively constant
in vivo. However, previous studies have demonstrated that, like many
other kinases such as glycogen synthase kinase 3 or CKII, CKI re-
quires a priming phosphorylation event at the −3 position for efficient
phosphorylation of the substrate [42].
Therefore, we reasoned that given the constant activity of CKI, the
priming kinase might determine the timing of the CKI-mediated
phosphorylation and subsequent destruction of the substrate. In this
regard, our work further showed that, although ectopic expression
of CKI greatly enhanced DEPTOR interaction with β-TrCP, this
effect was significantly reduced on mTOR inhibition [18]. Further-
more, using mass spectrometry analysis, we found that mTOR could
phosphorylate DEPTOR at pS265, pS286, pS293, pT295, and
pS299 [18]. This result suggests that mTOR might be the sought-
after priming kinase, which phosphorylates DEPTOR to trigger sub-
sequent CKI-mediated phosphorylation of DEPTOR at the pS286
or pS287 sites within the identified phospho-degron. In keeping
with this idea, the study from Pagano et al. found that mTOR
phosphorylates Ser293 and Ser299 to promote degron phosphoryla-
tion by CKIα [17]. Interestingly, Dr Sun’s group demonstrated
that DEPTOR is phosphorylated by S6K1 and RSK1 (ribosomal S6
kinase 1) on the three identified serine residues (Ser286, Ser287, and
Ser291) on serum stimulation. Specifically, S6K1 could act as a prime
kinase to facilitate DEPTOR phosphorylation by RSK1, resulting
in β-TrCP binding and subsequent DEPTOR ubiquitination and
degradation [19]. Because both RSK1 and S6K are the mTOR down-
stream signaling pathways that could be activated by serum stimula-
tion, without a doubt, we recognize that more thorough studies
are required to investigate the critical role of mTOR/S6K/RSK1 in a
phosphorylation-dependent degradation of DEPTOR.
Regulation of DEPTOR in Specific Conditions
Our studies revealed that DEPTOR protein levels are increased
under unfavorable conditions, contributing to the suppression of
mTOR kinase activity. More importantly, we found that DEPTOR
is rapidly degraded in an mTOR-dependent manner when cells
are under favorable conditions to allow for the timely activation of
the mTOR signaling pathway. Therefore, our studies provide ex-
perimental evidence to reveal the dual inhibitory nature between
DEPTOR and mTOR, which allows the formation of an intricate
regulatory circuit to govern the timely response of mTOR kinase
activity to environmental stresses. As a result, in response to unfavor-
able conditions, reduced mTOR activity leads to impaired DEPTOR
destruction and further reduction in mTOR signaling. However, in
response to growth-stimulatory signals, induction of mTOR kinase
activity leads to rapid destruction of DEPTOR and further facil-
itating the activation of mTOR signaling. Thus, our study expands
the current understanding of the physiological function of β-TrCP
by pinpointing its critical role in regulating mTOR activity, by
which β-TrCP may participate in governing cellular metabolism and
nutrient sensing.
Role of DEPTOR in Human Cancers
The function of DEPTOR in tumorigenesis is still controversial. Be-
cause DEPTOR binds and inhibits mTOR, whose activity is mostly
hyperactivated in many human tumors, DEPTOR is considered as
a tumor suppressor protein. Indeed, down-regulation of DEPTOR
has been found in many types of human cancers [17,47]. How-
ever, DEPTOR has been found to be overexpressed in many other
tumor types including breast cancer, prostate cancer, chronic myeloid
leukemia, and lung cancer [17,48–51]. For example, DEPTOR is
overexpressed in multiple myeloma cells, and this overexpression is
necessary for Akt activation and cell survival [16]. Recently, Pei et al.
[52] reported that DEPTOR is significantly increased in thyroid car-
cinoma cells and tissues compared with normal cells and adjacent
normal tissues. Moreover, DEPTOR expression is associated with
lymph node status and distant metastasis [52]. Furthermore, pa-
tients diagnosed with thyroid carcinoma exhibiting overexpression of
DEPTOR are susceptible to earlier recurrence and poorer survival, sug-
gesting that DEPTOR expression is an independent prognostic marker
for thyroid carcinoma [52]. In support of this notion, DEPTOR
expression was found to correlate with poor survival in patients
with multiple myeloma [53]. Taken together, the potential role of
DEPTOR as an oncogene or a tumor suppressor may be cell context
or tissue specific. In the following paragraphs, we will briefly discuss
the potential roles of DEPTOR in cell growth, apoptosis, autophagy,
epithelial-mesenchymal transition (EMT), and drug resistance.
Role of DEPTOR in Cell Growth
Accumulated evidence has suggested that DEPTOR plays a critical
role in tumor cell growth. Peterson et al. [16] found that suppression
of DEPTOR in multiple myeloma cells abolished cell proliferation,
overexpression of DEPTOR was necessary for maintaining cell sur-
vival, whereas up-regulation of DEPTOR contributes to Akt activa-
tion, in part by suppressing the ability of S6K to inactivate the IRS1/
PI3K/Akt signaling axis. Moreover, DEPTOR depletion increases cell
size, and rapamycin treatment reversed this phenotype [16]. These
results suggest that inhibiting DEPTOR expression or disrupting the
DEPTOR-mTOR interaction could be a promising strategy for better
treatment of multiple myeloma. Recently, Kazi et al. [54] found that
DEPTOR knockdown also increased the myoblast size and the rate
of proliferation. In addition, DEPTOR knockdown increased the
percent of cells in the S-phase, coincident with an increased pRb
phosphorylation [54]. However, the study from Dr Pagano’s group
showed that T98G cells expressing nondegradable mutant DEPTOR
displayed reduced cell size, arguing that up-regulation of DEPTOR
levels may be a viable therapeutic option for the treatment of human
cancers with low DEPTOR levels. Interestingly, Zhao et al. [19]
showed that DEPTOR accumulation inhibited cell death when cells
were grown at high-paclitaxel conditions, whereas DEPTOR knock-
down abrogated this cell growth inhibition. Furthermore, DEPTOR
plays a survival-promoting role under high-paclitaxel conditions in part
through activation of Akt and inhibition of paclitaxel-induced PARP
cleavage [19]. Although Akt has been indicated as a major signaling
node through which overexpressed DEPTOR may facilitate tumori-
genesis, suggesting that further in-depth investigation is warranted to
fully elucidate the role of DEPTOR in cell growth. We are also curious
to further understand whether there are mTOR-independent func-
tions of DEPTOR that contribute to this observed promoting role of
DEPTOR to cell growth and cell survival.
Role of DEPTOR in Apoptosis
DEPTOR has been reported to be involved in cell apoptosis [16].
Peterson et al. [16] demonstrated that down-regulation of DEPTOR
in HeLa cells protects cells from apoptosis due to increased poly ADP
ribose polymerase (PARP) and cleaved caspase 3. Specifically, reduc-
tions in the serum concentration of the medium caused a decrease in
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Akt phosphorylation and a decrease in the cleaved forms of caspase 3
and PARP in HeLa cells, whereas DEPTOR-deficient HeLa cells
were resistant to caspase 3 and PARP cleavage [16]. Moreover, they
showed that DEPTOR suppression protects HeLa cells from apoptosis
through inhibition of SGK1 activity [16]. Furthermore, inhibition of
DEPTOR also prevented caspase 3 cleavage in serum-deprived HT-29
cells [16], suggesting that DEPTOR plays a role in apoptosis in other
cancer cell line. However, it remains unclear whether this critical role
of DEPTOR in cellular apoptosis is largely owing to its inhibitory role
of mTOR kinase activity, and thus, further studies are required to
explore whether there is mTOR-independent function of DEPTOR
in governing cellular apoptotic pathways.
Role of DEPTOR in Autophagy
Recently, multiple groups have reported that DEPTOR is involved
in autophagy pathway. It is known that autophagy is a catabolic process
involving the massive degradation of cellular organelles and aggregate-
prone proteins in lysosomes [55]. Autophagy is a tightly regulated pro-
cess that allows the cells to maintain a balance between the synthesis,
degradation, and subsequent recycling of intracellular constituents [55].
Therefore, autophagy is considered as an alternative source of energy
to provide nutrients and energy in response to certain stresses such as
serum starvation [55]. It has been well accepted that autophagy has
a dual role as a key regulator of multiple aspects in human cancer
[56,57]. On the one hand, autophagy is a tumor suppressor mecha-
nism, which is connected to its roles in the prevention of oxidative
stress and genomic instability [57]. In this sense, autophagy can serve
as a barrier to limit tumor initiation. However, after neoplastic lesions
are established, tumor cells can exploit autophagy to survive in nutrient
starvation and hypoxic condition for malignant progression and tumor
maintenance. Tumor cells can also induce autophagy in response to
chemotherapeutics, leading to limiting drug efficacy [57]. There-
fore, the role of autophagy in cancer is rather complex, which could
be dependent on tumor type, stage, and the genetic context [56].
Recently, we and other groups reported that DEPTOR induced the
autophagy through suppression of the mTOR activity [18,19]. We
found that accumulation of DEPTOR by depletion of β-TrCP induced
LC3 autophagy marker. Moreover, we observed that overexpression
of a nondegradable form of DEPTOR led to a marked increase of
LC3-II and a decrease in p62 abundance, indicating that these cells
have an increased autophagic flux [18]. Furthermore, the autophagic
vesicle marker monodansylcadaverine is increased in these cells expres-
sing nondegradable DEPTOR. In addition, using Cherry-GFP-LC3B
fusion protein to measure autophagic flux, we observed an activation
of autophagy in HeLa cells after the absence of glucose, whereas deple-
tion of DEPTOR decreased autophagic flux on glucose deprivation
[18]. Consistent with our results, Dr Sun’s group also independently
found that DEPTOR knockdown blocks autophagy induced by glu-
cose deprivation, as evidenced by reduced levels of LC3-II [19]. In
addition, DEPTOR knockdown suppresses autophagy as evidenced
by p62 accumulation. More importantly, increased numbers of AO
(acridine orange)-positive cells as an autophagy marker on glucose
deprivation were inhibited by DEPTOR knockdown as well [19].
More recently, Liu et al. [58] found that transcriptional levels of
DEPTOR were increased time-dependently within 18 hours and then
decreased after nutrient depletion, suggesting that DEPTOR con-
tributes to autophagy in this process. Taken together, DEPTOR plays
a pivotal role in autophagy pathway in response to certain stresses such
as energy depletion, in part through negatively regulating the activity
of the mTOR signaling pathway, one of the well-characterized critical
regulators of the autophagy process.
Role of DEPTOR in EMT
Interestingly, DEPTOR has also been reported to be involved in
the EMT process [59]. EMT is a process that involves remarkable
morphologic changes from an epithelial cobblestone phenotype to an
elongated fibroblastic phenotype, including loss of cell-cell adhesion,
actin cytoskeleton reorganization, loss of cell polarity, and increased cell
motility and invasion [60]. Specifically, EMT has been characterized
by down-regulation of E-cadherin and up-regulation of mesenchymal
molecular markers such as vimentin, Snail, Slug, and fibronectin [60].
It is well accepted that EMT plays an important role in cancer invasion
and metastasis [60,61]. Recently, Chen et al. [59] demonstrated that
DEPTOR depletion could induce EMT in cancer cells by reducing
the expression of epithelial marker E-cadherin and inducing the
expression of mesenchymal marker N-cadherin. They also showed
that DEPTOR depletion increased the Snail protein in the nucleus.
Moreover, DEPTOR depletion also increased Akt phosphorylation,
suggesting that the Akt pathway may be involved in DEPTOR
depletion–mediated acquisition of EMT [59]. Furthermore, this group
found that big mitogen-activated protein kinase 1 suppresses EMT and
cancer metastasis through destabilization of Snail by the DEPTOR/
PI3K/mTORC2/Akt/glycogen synthase kinase 3β signaling pathways
[59]. Without a doubt, further studies are required to determine the
molecular mechanisms underlying DEPTOR depletion–mediated in-
duction of EMT, which will provide critical insights into whether
targeting DEPTOR could become a useful therapeutic strategy to
fight against metastatic cancers.
Potential Role of DEPTOR in Drug Resistance
Recently, we and others have shown that DEPTOR plays important
roles in the regulation of drug sensitivity [18,19,62]. Drug resistance
is the most common cause of tumor recurrence because it leads to
chemotherapeutic failure and fails to eliminate all tumor cells [63].
To that end, increasing drug sensitivity may shed light on the de-
velopment of novel strategy for achieving better treatment overcome
of human cancers. Therefore, we will briefly discuss the potential
function of DEPTOR in the regulation of drug resistance in the
following paragraphs.
A relatively large body of literature has demonstrated that DEPTOR is
associated with drug resistance in human malignancies [18,19,62].
For example, Dr Sun’s group reported that under β-TrCP knockdown/
DEPTOR-accumulated condition, cancer cells become more re-
sistant to rapamycin, an mTOR inhibitor whose cell growth inhibi-
tion depends on mTOR activity [19]. Moreover, the resistant to
rapamycin was rescued by knockdown of DEPTOR. This indicates
that DEPTOR expression might dictate the cellular response to mTOR
inhibitors, in part due to the inhibitory role of DEPTOR toward the
mTOR signaling pathway.
More interestingly, we found that, in a panel of multiple myeloma
cell lines, DEPTOR expression levels inversely correlate with their re-
sponsiveness to Velcade treatment [18]. Multiple myeloma cell lines
bearing a low expression of DEPTOR are much more sensitive to
Velcade than those with relatively high DEPTOR expression [18],
which seems to correlate with the unstable nature of DEPTOR that
accumulates on Velcade treatment to suppress mTOR kinase activity.
This might be because DEPTOR is accumulated to higher levels on
Velcade treatment, which suppresses the mTOR pathway to trigger
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cellular apoptosis. Further studies will be necessary to fully understand
whether DEPTOR is critical for Velcade sensitivity. In the meantime,
our work provides some rationale for designing targeted therapies for
multiple myeloma patients with Velcade; however, further work is
required to validate whether DEPTOR expression could be useful to
predict Velcade responsiveness.
More recently, Boyd et al. [64] demonstrated that a high DEPTOR
expression is associated with improved survival in patients treated
with thalidomide, suggesting that the expression levels of DEPTOR
are predictive of the response to thalidomide in myeloma. In addi-
tion, Foster et al. [62] reported that DEPTOR is highly expressed in
paclitaxel-resistant ovarian cancer cell lines, suggesting that, in a stage of
drug resistance, overexpression of DEPTOR could promote cancer
progression through increased survival. Consistently, Dr Sun’s group
demonstrated that cancer cells become more resistant to paclitaxel
after accumulation of DEPTOR [19]. To elucidate the mechanism
of paclitaxel resistance on DEPTOR accumulation, Dr Sun’s group
used multiple methods such as small interfering RNA knockdown of
Akt or RICTOR, inhibition of PI3K by LY294003, and inhibition
of mTORC1/2 by Torin. Importantly, they found that blockage of
mTORC1/2 and PI3K/Akt pathways largely abrogated paclitaxel resis-
tance [19], suggesting that DEPTOR-mediated paclitaxel resistance
is due to the activation of these two pathways. Although these recent
studies have shown a close relationship between DEPTOR expres-
sion and drug resistance, more thorough studies are required to further
understand the biologic significance of DEPTOR and the underlying
molecular mechanisms in conferring drug resistance under DEPTOR-
overexpressing conditions.
DEPTOR as a Potential Drug Target for
Cancer Therapy
Given the importance of DEPTOR in tumor cell growth, apoptosis,
autophagy, EMT, and drug resistance, DEPTOR has recently
emerged as an attractive pharmacological target for the development
of novel cancer therapy. In multiple myeloma cell lines with a high
expression of DEPTOR, inhibition of DEPTOR by its inhibitor could
be a therapeutic strategy for multiple myeloma. However, currently,
no such DEPTOR inhibitor has been developed. Nevertheless, up-
regulation of DEPTOR is needed for better treatment in human
cancers with a low expression of DEPTOR to regulate mTOR activity.
In this regard, Liu et al. [65,66] recently showed that resveratrol, a
naturally occurring polyphenol, promotes the interaction between
mTOR and DEPTOR, leading to inhibition of mTOR signaling.
The key question is how resveratrol increases the association between
mTOR and DEPTOR. The authors reasoned that resveratrol might
directly interact with mTOR or DEPTOR, resulting in an enhanced
interaction between these two proteins [66]. Another possibility is that
resveratrol indirectly promotes the interaction between mTOR and
DEPTOR through binding to an auxiliary protein [66]. Alternatively,
resveratrol may activate other signaling pathway that causes a chemical
modification of DEPTOR or mTOR, leading to enhanced interaction
between these proteins [66]. Because it has no experimental evidence
to tease out the exact molecular mechanism underlying the role of
resveratrol in regulating the mTOR pathway, further investigation is
required to formally test these possibilities. It is also interesting to
further explore whether other naturally occurring compounds could
deliver similar effects in regulating the DEPTOR/mTOR signaling
axis, thereby presenting as promising agents to treat pathologic condi-
tions with aberrant mTOR activation including diabetes and cancers.
Conclusion
In conclusion, DEPTOR plays a critical role in the development and
progression of human cancers by regulating many cellular processes
such as cell growth, apoptosis, autophagy, EMT, and drug resistance
(Figure 2). Moreover, DEPTOR has a dual role as tumor suppressor
gene or oncogene dependent on specific tumor types. Therefore, devel-
opment of inhibitors to target DEPTOR could be a novel strategy for
the treatment of cancers with a high expression of DEPTOR, whereas
up-regulation of DEPTOR may be a viable therapeutic option for can-
cers characterized by low DEPTOR levels and activation of mTOR.
One alternative strategy may be to target several signaling pathways
that control DEPTOR expression, such as CKI and β-TrCP. Further-
more, the natural compound resveratrol inhibits mTOR signaling by
targeting DEPTOR. Because of nontoxic features, targeting DEPTOR
by natural agents combined with conventional chemotherapeutics
could be a promising and safer approach for achieving better treatment
of human malignancies. However, because DEPTOR’s role in cancer
development seems to be tissue specific, further in-depth mechanistic
Figure 2. Illustrated presentation of the various potential functions of DEPTOR in different types of human cancers. GSK3β indicates
glycogen synthase kinase 3β; MM, multiple myeloma.
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studies are required to investigate the exact molecular mechanism how
DEPTOR affects the mTOR pathway in different tissues using novel
in vitro and animal models. Further testing is also required to test
whether DEPTOR expression could serve as a new predictive bio-
marker of response to chemotherapeutics for the treatment of various
types of human cancers.
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